...Phase II dose this quarter.Aisling’s Elms and Venrock’s...

...By Virginia Li, Associate Editor With its latest $450 million fund, Venrock has eschewed the broader...
...first-in-class therapies, genomics platforms and healthcare IT. According to the firm’s Bryan Roberts, about half of Venrock...
...LianBio and engineered microbe developer Federation Bio Inc. While more than a dozen VCs raised record funds last year, Venrock’s last...

...and commercial success, including a handful of ten-figure takeouts.The series B round was led by Venrock...
...translational medicine, and Eric Bischoff as SVP of development and operations.Bong Koh, the lead investor from Venrock...

...looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury at the time. RA Capital, Venrock...

...Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock...

...Farallon Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock...

...companies. A crossover syndicate is investing $91 million into the union; leader Fairmount Funds Management joins Venrock...

...NASDAQ:MYOK) and BridgeBio Pharma Inc. (NASDAQ:BBIO).RA Capital, Venrock...

...which saw participation from seed investors including Venrock...
...VP of BD at 23andMe Inc. She succeeds Venrock...
...enabling application beyond Clostridium difficile infections as a driver of Venrock’s...

...if the general markets are volatile,” she said. Venrock’s...